Back to All Combinations

MSI-H + BRAF V600E (Sporadic)

Intermediate Prognosis
2.50% Prevalence Level 1 Immunotherapy Biomarkers
Actionable Target
FDA-approved targeted therapies or strong clinical trial evidence available
Genes Involved
BRAF MLH1
Treatment Implications

Better than BRAF V600E/MSS. Usually sporadic with MLH1 methylation.

Recommended Treatments
Pembrolizumab
Nivolumab + Ipilimumab
Encorafenib + Cetuximab
Treatments to Avoid
Anti-EGFR monotherapy
Study References

BEACON CRC, CheckMate 142

Key Statistics
2.50%
Prevalence in CRC
Yes
Targetable
Clinical Notes
BRAF V600E + MLH1 methylation virtually excludes Lynch.
Information

Category: Immunotherapy Biomarkers

Evidence Level: Level 1

Last Updated: Dec 7, 2025

Related Combinations
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.